Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

BRUIN; NCT03740529
CLL/SLL or NHL
BTK Inhibitor Enrolling
LIBRETTO-531; NCT04211337
Medullary Thyroid Cancer
RET Inhibitor Enrolling
LIBRETTO-121; NCT03899792
Pediatric Cancer
RET Inhibitor Enrolling
EMBER; NCT04188548
Breast Cancer or Endometrial Cancer
Selective ER Degrader Enrolling